Dr. Rafael Blesa obtained his medical degree from the Universitat Autònoma de Barcelona in 1975 and specialized in Neurology at Hospital de la Santa Creu i Sant Pau.
After completing his Ph.D. in Medicine at the Universitat de Barcelona (1989) he worked at the National Institute of Health in Bethesda, Maryland (USA) as an associate researcher in experimental therapies. He returned to Barcelona in 1993 where he directed the Alzheimer and Other Cognitive Disorders Unit at Hospital Clínic for 10 years. Since 2003, Dr Blesa has been the Director of the Neurology Department at Hospital de la Santa Creu i Sant Pau.
Dr. Rafael Blesa is the author of more than 30 book chapters and more than 170 scientific articles published in high impact national and international journals, and he has been the principal investigator of over 70 research projects and pharmacological studies in the field of Alzheimer’s disease. He is a member of prestigious medical and scientific societies that have awarded his scientific contributions in numerous occasions.
In his professional trajectory, he has combined clinical and research tasks with teaching activities as an associate professor of Neurology at Universitat de Barcelona and Universitat Autònoma de Barcelona, and he has directed and supervised numerous doctoral theses.
- Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Alcolea, D et al. J. Neurol. Neurosurg. Psychiatry 2018PMID:30297518
- CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Illán-Gala, I et al. Neurology 2018PMID:30291183
- Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Bergeron, D et al. Ann. Neurol. 2018PMID:30255971
- A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Zhang, M et al. Brain 2018PMID:30252044
- Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species. Oliveira, F et al. Neuroimage Clin 2018PMID:30186764
- Challenges associated with biomarker-based classification systems for Alzheimer's disease. Illán-Gala, I et al. Alzheimers Dement (Amst) 2018PMID:30175226
- Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J et al. Lancet Neurol 2018PMID:30172624
- Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Blesa, R et al. Curr Alzheimer Res 2018PMID:29895249
- Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Morenas-Rodríguez, E et al. J. Alzheimers Dis. 2018PMID:29889064
- Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Cortés-Vicente, E et al. Dement Geriatr Cogn Disord 2018PMID:29886477
- Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. Dekker, AD et al. Alzheimers Dement (Amst) 2018PMID:29780859
- The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Dekker, AD et al. J. Alzheimers Dis. 2018PMID:29689719
- Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Cantero, JL et al. Neurobiol. Aging 2018PMID:29331877
- Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. Broce, I et al. PLoS Med. 2018PMID:29315334
- Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Jimenez, A et al. Oncotarget 2017PMID:29285207